Business
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Set to Report Q1 Earnings in Wake of HOPE's Strategic Kadima Agreement
This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. LOS ANGELES, CA - May 15, 2025 (NEWMEDIAWIRE) - NRx Pharmaceuticals Inc. (NASDAQ: NRXP) is scheduled to ...
About this update from Nrx Pharmaceuticals, Inc.
[{"type":"text","content":"This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community.","length":145,"tagName":"p"},{"type":"text","content":"LOS ANGELES, CA - May 15, 2025 (NEWMEDIAWIRE) - NRx Pharmaceuticals Inc. (NASDAQ: NRXP) is scheduled to report its first quarter 2025 financial results after the market closes on Thursday, May 15. A conference call and webcast will follow at 4:30 p.m. ET, accessible via the company's investor relations site or by dialing +1-800-717-1738 (U.S.) or +1-646-307-1865 (international).","length":385,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":"Investor Brand Network","className":"","disableSlideshowImg":false,"size":{"original":{"width":1400,"height":800,"url":"https://media.zenfs.com/en/newsmediawire_165/8cf86e9dcea922a44a00ee80d6d26b51"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/x2p8bJZIReaGhU0FitMjVw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0OTtjZj13ZWJw/https://media.zenfs.com/en/newsmediawire_165/8cf86e9dcea922a44a00ee80d6d26b51","width":960,"height":549},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/TR9Wpo.VK9Wcyn6gwudfEA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xMzcyO2NmPXdlYnA-/https://media.zenfs.com/en/newsmediawire_165/8cf86e9dcea922a44a00ee80d6d26b51","width":1200,"height":686}}},{"type":"text","content":"The earnings update comes shortly after news that NRx's wholly owned subsidiary, HOPE Therapeutics, signed a definitive agreement to acquire Kadima Neuropsychiatry Institute in La Jolla, California. Kadima is a profitable clinic and leader in psychedelic and neuroplastic research, offering treatments for suicidal depression, PTSD and other CNS conditions. It is expected to serve as the model for HOPE's national clinic rollout.","length":438,"tagName":"p"},{"type":"text","content":"To view the full press release announcing the Kadima agreement, visit https://ibn.fm/sxSUl","length":90,"tagName":"p"},{"type":"text","content":"About NRx Pharmaceuticals Inc. ","length":30,"tagName":"p"},{"type":"text","content":"NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The company is...